Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 29 entries
Sorted by: Best Match Show Resources per page
A novel temporary keratoprosthesis technique for vitreoretinal surgery.

International journal of ophthalmology

Skevas C, Bigdon E, Steinhorst A, Katz T, Schindler P, Kromer R, Spitzer MS.
PMID: 34804872
Int J Ophthalmol. 2021 Nov 18;14(11):1791-1795. doi: 10.18240/ijo.2021.11.21. eCollection 2021.

AIM: To investigate the safety of vitreoretinal surgery when using a soft contact lens as a temporary keratoprosthesis (TKP) in patients with severe corneal opacifications.METHODS: Three patients with simultaneous corneal and vitreoretinal pathology were treated with a soft contact...

Cite
Skevas C, Bigdon E, Steinhorst A, et al. A novel temporary keratoprosthesis technique for vitreoretinal surgery. Int J Ophthalmol. 2021;14(11):1791-1795doi: 10.18240/ijo.2021.11.21.
Skevas, C., Bigdon, E., Steinhorst, A., Katz, T., Schindler, P., Kromer, R., & Spitzer, M. S. (2021). A novel temporary keratoprosthesis technique for vitreoretinal surgery. International journal of ophthalmology, 14(11), 1791-1795. https://doi.org/10.18240/ijo.2021.11.21
Skevas, Christos, et al. "A novel temporary keratoprosthesis technique for vitreoretinal surgery." International journal of ophthalmology vol. 14,11 (2021): 1791-1795. doi: https://doi.org/10.18240/ijo.2021.11.21
Skevas C, Bigdon E, Steinhorst A, Katz T, Schindler P, Kromer R, Spitzer MS. A novel temporary keratoprosthesis technique for vitreoretinal surgery. Int J Ophthalmol. 2021 Nov 18;14(11):1791-1795. doi: 10.18240/ijo.2021.11.21. eCollection 2021. PMID: 34804872; PMCID: PMC8569565.
Copy Download .nbib Format: NLM
USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.

The Lancet. Oncology

Tammemägi MC, Ruparel M, Tremblay A, Myers R, Mayo J, Yee J, Atkar-Khattra S, Yuan R, Cressman S, English J, Bedard E, MacEachern P, Burrowes P, Quaife SL, Marshall H, Yang I, Bowman R, Passmore L, McWilliams A, Brims F, Lim KP, Mo L, Melsom S, Saffar B, Teh M, Sheehan R, Kuok Y, Manser R, Irving L, Steinfort D, McCusker M, Pascoe D, Fogarty P, Stone E, Lam DCL, Ng MY, Vardhanabhuti V, Berg CD, Hung RJ, Janes SM, Fong K, Lam S.
PMID: 34902336
Lancet Oncol. 2022 Jan;23(1):138-148. doi: 10.1016/S1470-2045(21)00590-8. Epub 2021 Dec 11.

BACKGROUND: Lung cancer is a major health problem. CT lung screening can reduce lung cancer mortality through early diagnosis by at least 20%. Screening high-risk individuals is most effective. Retrospective analyses suggest that identifying individuals for screening by accurate...

Cite
Tammemägi MC, Ruparel M, Tremblay A, et al. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. Lancet Oncol. 2021;23(1):138-148doi: 10.1016/S1470-2045(21)00590-8.
Tammemägi, M. C., Ruparel, M., Tremblay, A., Myers, R., Mayo, J., Yee, J., Atkar-Khattra, S., Yuan, R., Cressman, S., English, J., Bedard, E., MacEachern, P., Burrowes, P., Quaife, S. L., Marshall, H., Yang, I., Bowman, R., Passmore, L., McWilliams, A., Brims, F., Lim, K. P., Mo, L., Melsom, S., Saffar, B., Teh, M., Sheehan, R., Kuok, Y., Manser, R., Irving, L., Steinfort, D., McCusker, M., Pascoe, D., Fogarty, P., Stone, E., Lam, D. C. L., Ng, M. Y., Vardhanabhuti, V., Berg, C. D., Hung, R. J., Janes, S. M., Fong, K., & Lam, S. (2022). USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. The Lancet. Oncology, 23(1), 138-148. https://doi.org/10.1016/S1470-2045(21)00590-8
Tammemägi, Martin C, et al. "USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study." The Lancet. Oncology vol. 23,1 (2022): 138-148. doi: https://doi.org/10.1016/S1470-2045(21)00590-8
Tammemägi MC, Ruparel M, Tremblay A, Myers R, Mayo J, Yee J, Atkar-Khattra S, Yuan R, Cressman S, English J, Bedard E, MacEachern P, Burrowes P, Quaife SL, Marshall H, Yang I, Bowman R, Passmore L, McWilliams A, Brims F, Lim KP, Mo L, Melsom S, Saffar B, Teh M, Sheehan R, Kuok Y, Manser R, Irving L, Steinfort D, McCusker M, Pascoe D, Fogarty P, Stone E, Lam DCL, Ng MY, Vardhanabhuti V, Berg CD, Hung RJ, Janes SM, Fong K, Lam S. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. Lancet Oncol. 2022 Jan;23(1):138-148. doi: 10.1016/S1470-2045(21)00590-8. Epub 2021 Dec 11. PMID: 34902336; PMCID: PMC8716337.
Copy Download .nbib Format: NLM
Emerging and multifaceted role of neutrophils in lung cancer.

Translational lung cancer research

Aloe C, Wang H, Vlahos R, Irving L, Steinfort D, Bozinovski S.
PMID: 34295679
Transl Lung Cancer Res. 2021 Jun;10(6):2806-2818. doi: 10.21037/tlcr-20-760.

It has long been recognized that cigarette smoking is a shared risk factor for lung cancer and the debilitating lung disease, chronic obstructive pulmonary disease (COPD). As the severity of COPD increases, so does the risk for developing lung...

Cite
Aloe C, Wang H, Vlahos R, et al. Emerging and multifaceted role of neutrophils in lung cancer. Transl Lung Cancer Res. 2021;10(6):2806-2818doi: 10.21037/tlcr-20-760.
Aloe, C., Wang, H., Vlahos, R., Irving, L., Steinfort, D., & Bozinovski, S. (2021). Emerging and multifaceted role of neutrophils in lung cancer. Translational lung cancer research, 10(6), 2806-2818. https://doi.org/10.21037/tlcr-20-760
Aloe, Christian, et al. "Emerging and multifaceted role of neutrophils in lung cancer." Translational lung cancer research vol. 10,6 (2021): 2806-2818. doi: https://doi.org/10.21037/tlcr-20-760
Aloe C, Wang H, Vlahos R, Irving L, Steinfort D, Bozinovski S. Emerging and multifaceted role of neutrophils in lung cancer. Transl Lung Cancer Res. 2021 Jun;10(6):2806-2818. doi: 10.21037/tlcr-20-760. PMID: 34295679; PMCID: PMC8264329.
Copy Download .nbib Format: NLM
Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors.

Translational lung cancer research

Rangamuwa K, Leong T, Weeden C, Asselin-Labat ML, Bozinovski S, Christie M, John T, Antippa P, Irving L, Steinfort D.
PMID: 34295682
Transl Lung Cancer Res. 2021 Jun;10(6):2842-2857. doi: 10.21037/tlcr-20-1075.

Lung cancer is the leading cause of cancer death worldwide, with approximately 1.6 million cancer related deaths each year. Prognosis is best in patients with early stage disease, though even then five-year survival is only 55% in some groups....

Cite
Rangamuwa K, Leong T, Weeden C, et al. Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Transl Lung Cancer Res. 2021;10(6):2842-2857doi: 10.21037/tlcr-20-1075.
Rangamuwa, K., Leong, T., Weeden, C., Asselin-Labat, M. L., Bozinovski, S., Christie, M., John, T., Antippa, P., Irving, L., & Steinfort, D. (2021). Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Translational lung cancer research, 10(6), 2842-2857. https://doi.org/10.21037/tlcr-20-1075
Rangamuwa, Kanishka, et al. "Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors." Translational lung cancer research vol. 10,6 (2021): 2842-2857. doi: https://doi.org/10.21037/tlcr-20-1075
Rangamuwa K, Leong T, Weeden C, Asselin-Labat ML, Bozinovski S, Christie M, John T, Antippa P, Irving L, Steinfort D. Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Transl Lung Cancer Res. 2021 Jun;10(6):2842-2857. doi: 10.21037/tlcr-20-1075. PMID: 34295682; PMCID: PMC8264311.
Copy Download .nbib Format: NLM
USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.

The Lancet. Oncology

Tammemägi MC, Ruparel M, Tremblay A, Myers R, Mayo J, Yee J, Atkar-Khattra S, Yuan R, Cressman S, English J, Bedard E, MacEachern P, Burrowes P, Quaife SL, Marshall H, Yang I, Bowman R, Passmore L, McWilliams A, Brims F, Lim KP, Mo L, Melsom S, Saffar B, Teh M, Sheehan R, Kuok Y, Manser R, Irving L, Steinfort D, McCusker M, Pascoe D, Fogarty P, Stone E, Lam DCL, Ng MY, Vardhanabhuti V, Berg CD, Hung RJ, Janes SM, Fong K, Lam S.
PMID: 34902336
Lancet Oncol. 2021 Dec 10; doi: 10.1016/S1470-2045(21)00590-8. Epub 2021 Dec 10.

BACKGROUND: Lung cancer is a major health problem. CT lung screening can reduce lung cancer mortality through early diagnosis by at least 20%. Screening high-risk individuals is most effective. Retrospective analyses suggest that identifying individuals for screening by accurate...

Cite
Tammemägi MC, Ruparel M, Tremblay A, et al. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. Lancet Oncol. 2021;doi: 10.1016/S1470-2045(21)00590-8.
Tammemägi, M. C., Ruparel, M., Tremblay, A., Myers, R., Mayo, J., Yee, J., Atkar-Khattra, S., Yuan, R., Cressman, S., English, J., Bedard, E., MacEachern, P., Burrowes, P., Quaife, S. L., Marshall, H., Yang, I., Bowman, R., Passmore, L., McWilliams, A., Brims, F., Lim, K. P., Mo, L., Melsom, S., Saffar, B., Teh, M., Sheehan, R., Kuok, Y., Manser, R., Irving, L., Steinfort, D., McCusker, M., Pascoe, D., Fogarty, P., Stone, E., Lam, D. C. L., Ng, M. Y., Vardhanabhuti, V., Berg, C. D., Hung, R. J., Janes, S. M., Fong, K., & Lam, S. (2021). USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. The Lancet. Oncology, . https://doi.org/10.1016/S1470-2045(21)00590-8
Tammemägi, Martin C, et al. "USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study." The Lancet. Oncology vol. (2021). doi: https://doi.org/10.1016/S1470-2045(21)00590-8
Tammemägi MC, Ruparel M, Tremblay A, Myers R, Mayo J, Yee J, Atkar-Khattra S, Yuan R, Cressman S, English J, Bedard E, MacEachern P, Burrowes P, Quaife SL, Marshall H, Yang I, Bowman R, Passmore L, McWilliams A, Brims F, Lim KP, Mo L, Melsom S, Saffar B, Teh M, Sheehan R, Kuok Y, Manser R, Irving L, Steinfort D, McCusker M, Pascoe D, Fogarty P, Stone E, Lam DCL, Ng MY, Vardhanabhuti V, Berg CD, Hung RJ, Janes SM, Fong K, Lam S. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. Lancet Oncol. 2021 Dec 10; doi: 10.1016/S1470-2045(21)00590-8. Epub 2021 Dec 10. PMID: 34902336.
Copy Download .nbib Format: NLM
Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models.

Chest

Martinez-Zayas G, Almeida FA, Yarmus L, Steinfort D, Lazarus DR, Simoff MJ, Saettele T, Murgu S, Dammad T, Duong DK, Mudambi L, Filner JJ, Molina S, Aravena C, Thiboutot J, Bonney A, Rueda AM, Debiane LG, Hogarth DK, Bedi H, Deffebach M, Sagar AS, Cicenia J, Yu DH, Cohen A, Frye L, Grosu HB, Gildea T, Feller-Kopman D, Casal RF, Machuzak M, Arain MH, Sethi S, Eapen GA, Lam L, Jimenez CA, Ribeiro M, Noor LZ, Mehta A, Song J, Choi H, Ma J, Li L, Ost DE.
PMID: 33932466
Chest. 2021 Sep;160(3):1108-1120. doi: 10.1016/j.chest.2021.04.048. Epub 2021 Apr 28.

BACKGROUND: Two models, the Help with the Assessment of Adenopathy in Lung cancer (HAL) and Help with Oncologic Mediastinal Evaluation for Radiation (HOMER), were recently developed to estimate the probability of nodal disease in patients with non-small cell lung...

Cite
Martinez-Zayas G, Almeida FA, Yarmus L, et al. Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models. Chest. 2021;160(3):1108-1120doi: 10.1016/j.chest.2021.04.048.
Martinez-Zayas, G., Almeida, F. A., Yarmus, L., Steinfort, D., Lazarus, D. R., Simoff, M. J., Saettele, T., Murgu, S., Dammad, T., Duong, D. K., Mudambi, L., Filner, J. J., Molina, S., Aravena, C., Thiboutot, J., Bonney, A., Rueda, A. M., Debiane, L. G., Hogarth, D. K., Bedi, H., Deffebach, M., Sagar, A. S., Cicenia, J., Yu, D. H., Cohen, A., Frye, L., Grosu, H. B., Gildea, T., Feller-Kopman, D., Casal, R. F., Machuzak, M., Arain, M. H., Sethi, S., Eapen, G. A., Lam, L., Jimenez, C. A., Ribeiro, M., Noor, L. Z., Mehta, A., Song, J., Choi, H., Ma, J., Li, L., & Ost, D. E. (2021). Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models. Chest, 160(3), 1108-1120. https://doi.org/10.1016/j.chest.2021.04.048
Martinez-Zayas, Gabriela, et al. "Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models." Chest vol. 160,3 (2021): 1108-1120. doi: https://doi.org/10.1016/j.chest.2021.04.048
Martinez-Zayas G, Almeida FA, Yarmus L, Steinfort D, Lazarus DR, Simoff MJ, Saettele T, Murgu S, Dammad T, Duong DK, Mudambi L, Filner JJ, Molina S, Aravena C, Thiboutot J, Bonney A, Rueda AM, Debiane LG, Hogarth DK, Bedi H, Deffebach M, Sagar AS, Cicenia J, Yu DH, Cohen A, Frye L, Grosu HB, Gildea T, Feller-Kopman D, Casal RF, Machuzak M, Arain MH, Sethi S, Eapen GA, Lam L, Jimenez CA, Ribeiro M, Noor LZ, Mehta A, Song J, Choi H, Ma J, Li L, Ost DE. Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models. Chest. 2021 Sep;160(3):1108-1120. doi: 10.1016/j.chest.2021.04.048. Epub 2021 Apr 28. PMID: 33932466.
Copy Download .nbib Format: NLM
The effect of changing the schedule of reinforcement upon duration of responding.

Journal of the experimental analysis of behavior

SCHAEFER HH, STEINHORST RA.
PMID: 14442342
J Exp Anal Behav. 1959 Oct;2:335-41. doi: 10.1901/jeab.1959.2-335.

No abstract available.

Cite
SCHAEFER HH, STEINHORST RA. The effect of changing the schedule of reinforcement upon duration of responding. J Exp Anal Behav. 1959;2:335-41doi: 10.1901/jeab.1959.2-335.
SCHAEFER, H. H., & STEINHORST, R. A. (1959). The effect of changing the schedule of reinforcement upon duration of responding. Journal of the experimental analysis of behavior, 2335-41. https://doi.org/10.1901/jeab.1959.2-335
SCHAEFER, H H, and STEINHORST, R A. "The effect of changing the schedule of reinforcement upon duration of responding." Journal of the experimental analysis of behavior vol. 2 (1959): 335-41. doi: https://doi.org/10.1901/jeab.1959.2-335
SCHAEFER HH, STEINHORST RA. The effect of changing the schedule of reinforcement upon duration of responding. J Exp Anal Behav. 1959 Oct;2:335-41. doi: 10.1901/jeab.1959.2-335. PMID: 14442342; PMCID: PMC1403908.
Copy Download .nbib Format: NLM
COVID-19: looking backward.

Internal medicine journal

Woolley I, Steinfort D, Szer J.
PMID: 34423545
Intern Med J. 2021 Aug;51(8):1203-1204. doi: 10.1111/imj.15461.

No abstract available.

Cite
Woolley I, Steinfort D, Szer J. COVID-19: looking backward. Intern Med J. 2021;51(8):1203-1204doi: 10.1111/imj.15461.
Woolley, I., Steinfort, D., & Szer, J. (2021). COVID-19: looking backward. Internal medicine journal, 51(8), 1203-1204. https://doi.org/10.1111/imj.15461
Woolley, Ian, et al. "COVID-19: looking backward." Internal medicine journal vol. 51,8 (2021): 1203-1204. doi: https://doi.org/10.1111/imj.15461
Woolley I, Steinfort D, Szer J. COVID-19: looking backward. Intern Med J. 2021 Aug;51(8):1203-1204. doi: 10.1111/imj.15461. PMID: 34423545; PMCID: PMC8652750.
Copy Download .nbib Format: NLM
Urinary Retention After Video-Assisted Thoracoscopic Surgery: Role of Neuromuscular Blockade Reversal.

Journal of cardiothoracic and vascular anesthesia

Daquioag TK, Mele NJ, Peterson DR, Steinhorst JD, Schultz SJ, Steege JR, Sprung J, Schroeder DR, Weingarten TN.
PMID: 34176678
J Cardiothorac Vasc Anesth. 2022 Jan;36(1):350-351. doi: 10.1053/j.jvca.2021.05.048. Epub 2021 May 27.

No abstract available.

Cite
Daquioag TK, Mele NJ, Peterson DR, et al. Urinary Retention After Video-Assisted Thoracoscopic Surgery: Role of Neuromuscular Blockade Reversal. J Cardiothorac Vasc Anesth. 2021;36(1):350-351doi: 10.1053/j.jvca.2021.05.048.
Daquioag, T. K., Mele, N. J., Peterson, D. R., Steinhorst, J. D., Schultz, S. J., Steege, J. R., Sprung, J., Schroeder, D. R., & Weingarten, T. N. (2022). Urinary Retention After Video-Assisted Thoracoscopic Surgery: Role of Neuromuscular Blockade Reversal. Journal of cardiothoracic and vascular anesthesia, 36(1), 350-351. https://doi.org/10.1053/j.jvca.2021.05.048
Daquioag, Troy K, et al. "Urinary Retention After Video-Assisted Thoracoscopic Surgery: Role of Neuromuscular Blockade Reversal." Journal of cardiothoracic and vascular anesthesia vol. 36,1 (2022): 350-351. doi: https://doi.org/10.1053/j.jvca.2021.05.048
Daquioag TK, Mele NJ, Peterson DR, Steinhorst JD, Schultz SJ, Steege JR, Sprung J, Schroeder DR, Weingarten TN. Urinary Retention After Video-Assisted Thoracoscopic Surgery: Role of Neuromuscular Blockade Reversal. J Cardiothorac Vasc Anesth. 2022 Jan;36(1):350-351. doi: 10.1053/j.jvca.2021.05.048. Epub 2021 May 27. PMID: 34176678.
Copy Download .nbib Format: NLM
Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models.

Chest

Martinez-Zayas G, Almeida FA, Yarmus L, Steinfort D, Lazarus DR, Simoff MJ, Saettele T, Murgu S, Dammad T, Duong DK, Mudambi L, Filner JJ, Molina S, Aravena C, Thiboutot J, Bonney A, Rueda AM, Debiane LG, Hogarth DK, Bedi H, Deffebach M, Sagar AS, Cicenia J, Yu DH, Cohen A, Frye L, Grosu HB, Gildea T, Feller-Kopman D, Casal RF, Machuzak M, Arain MH, Sethi S, Eapen GA, Lam L, Jimenez CA, Ribeiro M, Noor LZ, Mehta A, Song J, Choi H, Ma J, Li L, Ost DE.
PMID: 33932466
Chest. 2021 Sep;160(3):1108-1120. doi: 10.1016/j.chest.2021.04.048. Epub 2021 Apr 28.

BACKGROUND: Two models, the Help with the Assessment of Adenopathy in Lung cancer (HAL) and Help with Oncologic Mediastinal Evaluation for Radiation (HOMER), were recently developed to estimate the probability of nodal disease in patients with non-small cell lung...

Cite
Martinez-Zayas G, Almeida FA, Yarmus L, et al. Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models. Chest. 2021;160(3):1108-1120doi: 10.1016/j.chest.2021.04.048.
Martinez-Zayas, G., Almeida, F. A., Yarmus, L., Steinfort, D., Lazarus, D. R., Simoff, M. J., Saettele, T., Murgu, S., Dammad, T., Duong, D. K., Mudambi, L., Filner, J. J., Molina, S., Aravena, C., Thiboutot, J., Bonney, A., Rueda, A. M., Debiane, L. G., Hogarth, D. K., Bedi, H., Deffebach, M., Sagar, A. S., Cicenia, J., Yu, D. H., Cohen, A., Frye, L., Grosu, H. B., Gildea, T., Feller-Kopman, D., Casal, R. F., Machuzak, M., Arain, M. H., Sethi, S., Eapen, G. A., Lam, L., Jimenez, C. A., Ribeiro, M., Noor, L. Z., Mehta, A., Song, J., Choi, H., Ma, J., Li, L., & Ost, D. E. (2021). Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models. Chest, 160(3), 1108-1120. https://doi.org/10.1016/j.chest.2021.04.048
Martinez-Zayas, Gabriela, et al. "Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models." Chest vol. 160,3 (2021): 1108-1120. doi: https://doi.org/10.1016/j.chest.2021.04.048
Martinez-Zayas G, Almeida FA, Yarmus L, Steinfort D, Lazarus DR, Simoff MJ, Saettele T, Murgu S, Dammad T, Duong DK, Mudambi L, Filner JJ, Molina S, Aravena C, Thiboutot J, Bonney A, Rueda AM, Debiane LG, Hogarth DK, Bedi H, Deffebach M, Sagar AS, Cicenia J, Yu DH, Cohen A, Frye L, Grosu HB, Gildea T, Feller-Kopman D, Casal RF, Machuzak M, Arain MH, Sethi S, Eapen GA, Lam L, Jimenez CA, Ribeiro M, Noor LZ, Mehta A, Song J, Choi H, Ma J, Li L, Ost DE. Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models. Chest. 2021 Sep;160(3):1108-1120. doi: 10.1016/j.chest.2021.04.048. Epub 2021 Apr 28. PMID: 33932466.
Copy Download .nbib Format: NLM
Feasibility of pulse oximetry after water immersion.

Resuscitation plus

Holbery-Morgan L, Carew J, Angel C, Simpson N, Steinfort D, Radford S, Murphy M, Douglas N, Johnson D.
PMID: 34553181
Resusc Plus. 2021 Jun 29;7:100147. doi: 10.1016/j.resplu.2021.100147. eCollection 2021 Sep.

OBJECTIVE: This study aimed to determine if pulse oximetry could reliably be used after immersion in water, and if so, which of the finger, earlobe or nose most reliably produced a functional waveform.METHOD: Pulse oximetry data was recorded from...

Cite
Holbery-Morgan L, Carew J, Angel C, et al. Feasibility of pulse oximetry after water immersion. Resusc Plus. 2021;7:100147doi: 10.1016/j.resplu.2021.100147.
Holbery-Morgan, L., Carew, J., Angel, C., Simpson, N., Steinfort, D., Radford, S., Murphy, M., Douglas, N., & Johnson, D. (2021). Feasibility of pulse oximetry after water immersion. Resuscitation plus, 7100147. https://doi.org/10.1016/j.resplu.2021.100147
Holbery-Morgan, Lachlan, et al. "Feasibility of pulse oximetry after water immersion." Resuscitation plus vol. 7 (2021): 100147. doi: https://doi.org/10.1016/j.resplu.2021.100147
Holbery-Morgan L, Carew J, Angel C, Simpson N, Steinfort D, Radford S, Murphy M, Douglas N, Johnson D. Feasibility of pulse oximetry after water immersion. Resusc Plus. 2021 Jun 29;7:100147. doi: 10.1016/j.resplu.2021.100147. eCollection 2021 Sep. PMID: 34553181; PMCID: PMC8441519.
Copy Download .nbib Format: NLM
Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer.

Medical mycology case reports

Kuik KT, Trubiano J, Worth LJ, Harun NS, Steinfort D, Johnson D.
PMID: 25379397
Med Mycol Case Rep. 2014 Sep 16;6:34-6. doi: 10.1016/j.mmcr.2014.08.007. eCollection 2014 Oct.

Everolimus is an inhibitor of mammalian target of rapamycin with anti-tumour activity. While everolimus is known to cause drug-induced pneumonitis, it is rarely associated with Pneumocystis jirovecii pneumonia (PJP). We report a patient on everolimus therapy for metastatic breast...

Cite
Kuik KT, Trubiano J, Worth LJ, et al. Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer. Med Mycol Case Rep. 2014;6:34-6doi: 10.1016/j.mmcr.2014.08.007.
Kuik, K. T., Trubiano, J., Worth, L. J., Harun, N. S., Steinfort, D., & Johnson, D. (2014). Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer. Medical mycology case reports, 634-6. https://doi.org/10.1016/j.mmcr.2014.08.007
Kuik, Kelvin Teck-Hong, et al. "Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer." Medical mycology case reports vol. 6 (2014): 34-6. doi: https://doi.org/10.1016/j.mmcr.2014.08.007
Kuik KT, Trubiano J, Worth LJ, Harun NS, Steinfort D, Johnson D. Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer. Med Mycol Case Rep. 2014 Sep 16;6:34-6. doi: 10.1016/j.mmcr.2014.08.007. eCollection 2014 Oct. PMID: 25379397; PMCID: PMC4216328.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 29 entries